Samalizumab Treatment Group
|
Patient ID
|
Single Lesionb
|
Sum of Lesionsb
|
---|
% Change
|
Cycle Day
|
% Change
|
Cycle Day
|
---|
50 mg/m2 (N = 4)
|
101–103
|
−3.45
|
C1 D28
|
2.77
|
C1 D28
|
101–104
|
−45.29
|
C1 D77
|
−9.8
|
C1 D35
|
102–101
|
−19.75
|
C4 D16
|
4.32
|
C4 D16
|
102–102
|
−9.77
|
C1 D35
|
−9.46
|
C1 D35
|
100 mg/m2 (N = 4)a
|
101–202
|
−37.78
|
C4 D0
|
−6.83
|
C4 D0
|
101–203
|
−11.54
|
C4 D0
|
7.0
|
C1 D28
|
102–201
|
−95.31
|
C4 D0
|
−20.7
|
C4 D0
|
102–205
|
−41.36
|
C3 D26
|
−18.7
|
C3 D26
|
200 mg/m2 (N = 2)a
|
101–301
|
− 48.67
|
C1 D28
|
−28.7
|
C1 D28
|
102–303
|
−42.05
|
C3 D21
|
−4.75
|
C3 D21
|
300 mg/m2 (N = 3)
|
101–402
|
−14.29
|
C4 D43
|
8.3
|
C4 D43
|
101–403
|
−23.81
|
C1 D29
|
−12.5
|
C1 D29
|
102–401
|
−58.73
|
C1 D35
|
−16.1
|
C16 D1
|
400 mg/m2 (N = 3)
|
102–502
|
−87.02
|
C13 D35
|
−63.4
|
C13 D35
|
107–503
|
−54.55
|
C4 D27
|
−3.34
|
C1 D42
|
107–504
|
−29.34
|
C1 D29
|
9.52
|
C1 D29
|
500 mg/m2 (N = 4)a
|
101–606
|
−48.15
|
C6 D0
|
−6.91
|
C6 D0
|
102–601
|
−86.36
|
C2 D28
|
−73.7
|
C2 D28
|
102–603
|
−5.13
|
C1 D25
|
1.84
|
C1 D25
|
102–607
|
−37.36
|
C1 D28
|
−19.4
|
C1 D28
|
- aPatient 107–602 (500 mg/m2 cohort) did not have a post-dose CT scan and was not evaluable; Patients 104–204 (100 mg/m2 cohort) and 104–302 (200 mg/m2 cohort) had no reduction in any of their target lesions and are not included
- bMaximum reduction for a single lesion (product of bi-dimensional tumor measurement) and maximum reduction for sum of lesions (sum of the products of bi-dimensional tumor measurements) are presented as a % Change from baseline on the indicated Cycle and Day